These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


192 related items for PubMed ID: 11850123

  • 1. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
    Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL.
    Mol Cell Endocrinol; 2002 Jan 15; 186(1):69-79. PubMed ID: 11850123
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH, Burnstein KL.
    Endocrinology; 1998 Mar 01; 139(3):1197-207. PubMed ID: 9492054
    [Abstract] [Full Text] [Related]

  • 4. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
    Kokontis JM, Hay N, Liao S.
    Mol Endocrinol; 1998 Jul 01; 12(7):941-53. PubMed ID: 9658399
    [Abstract] [Full Text] [Related]

  • 5. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul 01; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 6. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines.
    Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA.
    Endocrinology; 2000 Jul 01; 141(7):2567-73. PubMed ID: 10875259
    [Abstract] [Full Text] [Related]

  • 7. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
    Zhuang SH, Schwartz GG, Cameron D, Burnstein KL.
    Mol Cell Endocrinol; 1997 Jan 03; 126(1):83-90. PubMed ID: 9027366
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
    Yang ES, Burnstein KL.
    J Biol Chem; 2003 Nov 21; 278(47):46862-8. PubMed ID: 12954644
    [Abstract] [Full Text] [Related]

  • 9. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1999 Mar 21; 140(3):1205-12. PubMed ID: 10067845
    [Abstract] [Full Text] [Related]

  • 10. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1997 Aug 21; 138(8):3290-8. PubMed ID: 9231780
    [Abstract] [Full Text] [Related]

  • 11. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
    Lu L, Schulz H, Wolf DA.
    BMC Cell Biol; 2002 Aug 20; 3():22. PubMed ID: 12188931
    [Abstract] [Full Text] [Related]

  • 12. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S.
    Prostate; 2005 Dec 01; 65(4):287-98. PubMed ID: 16015608
    [Abstract] [Full Text] [Related]

  • 13. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
    Flores O, Burnstein KL.
    Endocrinology; 2010 Oct 01; 151(10):4654-64. PubMed ID: 20739400
    [Abstract] [Full Text] [Related]

  • 14. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.
    Venkateswaran V, Klotz LH, Fleshner NE.
    Cancer Res; 2002 May 01; 62(9):2540-5. PubMed ID: 11980647
    [Abstract] [Full Text] [Related]

  • 15. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
    Qiao S, Tuohimaa P.
    Biochem Biophys Res Commun; 2004 Jun 25; 319(2):358-68. PubMed ID: 15178414
    [Abstract] [Full Text] [Related]

  • 16. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
    Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ.
    Mol Cell Endocrinol; 1997 Jan 03; 126(1):59-73. PubMed ID: 9027364
    [Abstract] [Full Text] [Related]

  • 17. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
    Moffatt KA, Johannes WU, Hedlund TE, Miller GJ.
    Cancer Res; 2001 Oct 01; 61(19):7122-9. PubMed ID: 11585744
    [Abstract] [Full Text] [Related]

  • 18. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Oct 01; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 19. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth.
    Carey JL, Sasur LM, Kawakubo H, Gupta V, Christian B, Bailey PM, Maheswaran S.
    Mol Endocrinol; 2004 Mar 01; 18(3):696-707. PubMed ID: 14684851
    [Abstract] [Full Text] [Related]

  • 20. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
    Bao BY, Hu YC, Ting HJ, Lee YF.
    Oncogene; 2004 Apr 22; 23(19):3350-60. PubMed ID: 15048085
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.